Qrar360

Sukuk Capital SME Financing (Sukuk Issuance)

Sukuk Capital · SME & Business Finance

Not yet scored

This product does not have a published Qrar360 Score yet. A score is published only when enough of its facts are verified from official sources to meet our coverage and confidence thresholds. The recorded facts below remain discoverable and comparable.

Compare this product

Compare it side by side with another product in the same category and market.

Overview

Sukuk Capital arranges sukuk issuances that let Saudi companies raise working-capital, project and asset-purchase financing of up to SAR 30 million from platform investors, with long-term tenors of up to 10 years. The platform states it sends a financing offer within 3 business days and disburses within 10 business days of complete data, charges an administrative fee of between 3% and 5% to the company, allows early settlement without additional fees, and takes a promissory note from the company and its owners (with real-estate mortgages or receivables assignment in some cases). Applicants must be companies (not sole establishments) with audited financial statements and a valid Saudi commercial registration.

Product TypeSME & Business Finance
Primary CurrencySAR
Sharia StatusSharia-compliant

Eligibility Requirements

No eligibility requirements are currently recorded for this product.

Availability by Country

No country availability data is currently available.

Provided By

This product is provided by Sukuk Capital. For the institution's licenses and regulatory status, see its profile page.

Other products in this category

Last Reviewed

This product has not yet been reviewed.

Verification Status

This product's data has been reviewed and verified against an official source.

A published official source is available for this product.
The information shown is based on data available to Qrar360 and may not reflect the institution's latest changes. Please verify with the product's official source before making any financial decision. This content does not constitute financial advice and does not rank or favor any product.